Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Persistence of Mutations during Remission in 114 AML Patients

Martin Culen, PhD, Zdenka Kosarova, MSc, Ivana Jeziskova, PhD, Adam Folta, PhD, Nikola Tom, MSc, Ondrej Venglár, Dana Dvorakova, PhD, Jiri Mayer, MD, Zdenek Racil

Blood (2018) 132 (Supplement 1): 2796.

https://doi.org/10.1182/blood-2018-99-110586

Published: 2018

Journal Articles

Simulation of AML Clonality in Patient-Derived Xenografts

Zdenka Kosarova, MSc, Martin Culen, PhD, Ivana Jeziskova, PhD, Adam Folta, PhD, Veronika Janeckova, PhD, Jana Cerna, PhD, Tomas Loja, PhD, Nikola Tom, MSc, Lukas Semerad, MD, Zuzana Sustkova, MD, Dana Dvorakova, PhD, Jiri Mayer, Prof, MD SCs, Zdenek Racil, MD

Blood (2017) 130 (Supplement 1): 3915.

https://doi.org/10.1182/blood.V130.Suppl_1.3915.3915

Published: 2017

Journal Articles

Cytogenetic Aberration Profile of Chronic Myeloid Leukemia and Its Dynamic Changes During Imatinib Therapy,

Jelena D. Milosevic, Filip Razga, Dana Dvorakova, Tomas Jurcek, Tiina Berg, Ana Puda, Thorsten Klampfl, Ashot Harutyunyan, Bettina Gisslinger, Heinz Gisslinger, MD, Ester Orlandi, Paolo Bernasconi, Karel Indrak, Martina Divoka, Edgar Faber, Jiri Mayer, MD, Zdenek Racil, Robert Kralovics, PhD

Blood (2011) 118 (21): 3755.

https://doi.org/10.1182/blood.V118.21.3755.3755

Published: 2011

Journal Articles

Distinct Genetic Lesions Drive Leukemogenesis in Secondary Acute Myeloid Leukemia,

Blood (2011) 118 (21): 3559.

https://doi.org/10.1182/blood.V118.21.3559.3559

Published: 2011

Journal Articles

Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA

Blood (2010) 116 (22): e111–e117.

https://doi.org/10.1182/blood-2010-06-291641

Published: 2010

Includes: Supplemental data

Journal Articles

Minimal Residual Resistance In CML: Stable BCR-ABL Gene Expression at Levels 0.01–0.1% (IS) In the Consecutive Samples May Be Associated with BCR-ABL Mutation Development and MMoR Lost In a Small Number of Tyrosine Kinase Inhibitor Responders.

Katerina Machova Polakova, Sylvie Nadvornikova, Karla Zemanova, Hana Klamova, Tomas Jurcek, Dana Dvorakova, Daniela Zackova, Jiri Mayer, Marek Trneny, Jana Moravcova

Blood (2010) 116 (21): 3419.

https://doi.org/10.1182/blood.V116.21.3419.3419

Published: 2010

Journal Articles

The Plateau of BCR-ABL Transcript Level ≥0.1% May Select CML Patients in Complete Cytogenetic Remission for Mutation Analysis.

Katerina Machova Polakova, Vaclava Polivkova, Jana Rulcova, Hana Klamova, Tomas Jurcek, Dana Dvorakova, Daniela Zackova, Zdenek Pospisil, Jirí Mayer, Jana Moravcova

Blood (2009) 114 (22): 2216.

https://doi.org/10.1182/blood.V114.22.2216.2216

Published: 2009

Journal Articles

Monitoring of Minimal Residual Disease in NPM1 Mutated Acute Myeloid Leukemia (AML) – a Single Center Experience in 27 Patients.

Dana Dvorakova, Zdenek Racil, Ivo Palasek, Marketa Protivankova, Ivana Jeziskova, Martina Lengerova, Jiri Mayer

Blood (2009) 114 (22): 4672.

https://doi.org/10.1182/blood.V114.22.4672.4672

Published: 2009

Journal Articles

Chimerism Status as a Possible Marker of Incipient Disease Relapse in Patients with AML.

Ondrej Horky, MSc, Jiri Mayer, Prof., Marek Borky, MSc., Marta Krejci, MD, Sarka Pospisilova, PhD, Dana Dvorakova, PhD

Blood (2007) 110 (11): 5028.

https://doi.org/10.1182/blood.V110.11.5028.5028

Published: 2007

Journal Articles

Detection and Treatment of Molecular Relapse in Acute Myeloid Leukemia with RUNX1, CBFB or MLL Gene Translocations. Frequent Quantitative Monitoring of Molecular Markers in Different Compartments and Correlation with WT1 Gene Expression.

Michael Doubek, MD, PhD, Ivo Palasek, MD, Zdenek Pospisil, PhD, Sona Struncova, PhD, Dana Dvorakova, PhD, Marek Borsky, PhD, Martin Klabusay, PhD, Yvona Brychtova, MD, Marta Krejci, MD, PhD, Jiri Mayer, MD, PhD

Blood (2007) 110 (11): 4356.

https://doi.org/10.1182/blood.V110.11.4356.4356

Published: 2007

Journal Articles

Detection of Molecular Relapse of AML by Very Frequent Quantitative Monitoring of Different Molecular Markers (Fusion Transcripts and WT1) in Different Compartments (Peripheral Blood-PB, Bone Marrow-BM, and Selected CD34+ Bone Marrow Cells) and Its Treatment with Chemotherapy or Gemtuzumab Ozogamicin.

Jiri Mayer, Ivo Palasek, Zdenek Pospisil, Sona Struncova, Dana Dvorakova, Marek Borsky, Martin Klabusay, Michael Doubek, Yvona Brychtova, Zdenek Racil

Blood (2006) 108 (11): 4481.

https://doi.org/10.1182/blood.V108.11.4481.4481

Published: 2006

Journal Articles

Constitutive Activation of STAT1 and STAT3 Proteins on Serine and Tyrosine Residues Were Found in Majority of CLL Patients.

Jitka Chumchalova, PhD, Dana Klimesova, MSc, Viera Kuhrova, Hana Francova, MSc, Yvona Brychtova, MD, Michael Doubek, MD, Dana Dvorakova, PhD, Jiri Mayer, MD

Blood (2006) 108 (11): 4931.

https://doi.org/10.1182/blood.V108.11.4931.4931

Published: 2006

Journal Articles

Fibroblast Growth Factor Receptors in Human Embryonic Stem Cells.

Dana Dvorakova, PhD, Stanislava Koskova, Martina Vodinska, MVD, Ales Hampl, MVD, PhD, Jiri Mayer, MD, PhD, Petr Dvorak, PhD

Blood (2004) 104 (11): 4168.

https://doi.org/10.1182/blood.V104.11.4168.4168

Published: 2004

NARROW

Persistence of Mutations during Remission in 114 AML Patients

Simulation of AML Clonality in Patient-Derived Xenografts

Cytogenetic Aberration Profile of Chronic Myeloid Leukemia and Its Dynamic Changes During Imatinib Therapy,

Distinct Genetic Lesions Drive Leukemogenesis in Secondary Acute Myeloid Leukemia,

Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA

Minimal Residual Resistance In CML: Stable BCR-ABL Gene Expression at Levels 0.01–0.1% (IS) In the Consecutive Samples May Be Associated with BCR-ABL Mutation Development and MMoR Lost In a Small Number of Tyrosine Kinase Inhibitor Responders.

The Plateau of BCR-ABL Transcript Level ≥0.1% May Select CML Patients in Complete Cytogenetic Remission for Mutation Analysis.

Monitoring of Minimal Residual Disease in NPM1 Mutated Acute Myeloid Leukemia (AML) – a Single Center Experience in 27 Patients.

Chimerism Status as a Possible Marker of Incipient Disease Relapse in Patients with AML.

Detection and Treatment of Molecular Relapse in Acute Myeloid Leukemia with RUNX1, CBFB or MLL Gene Translocations. Frequent Quantitative Monitoring of Molecular Markers in Different Compartments and Correlation with WT1 Gene Expression.

Constitutive Activation of STAT1 and STAT3 Proteins on Serine and Tyrosine Residues Were Found in Majority of CLL Patients.

Fibroblast Growth Factor Receptors in Human Embryonic Stem Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only